Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Short-Term Debt repayments (2019 - 2025)

China Pharma Holdings' Short-Term Debt repayments history spans 7 years, with the latest figure at $701411.0 for Q4 2025.

  • For Q4 2025, Short-Term Debt repayments changed N/A year-over-year to $701411.0; the TTM value through Dec 2025 reached $1.2 million, down 48.45%, while the annual FY2025 figure was $1.2 million, 138.72% up from the prior year.
  • Short-Term Debt repayments reached $701411.0 in Q4 2025 per CPHI's latest filing, up from -$617961.0 in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $1.5 million in Q3 2021 to a low of -$617961.0 in Q3 2025.
  • Average Short-Term Debt repayments over 4 years is $529052.2, with a median of $701411.0 recorded in 2025.
  • The largest YoY upside for Short-Term Debt repayments was 1367.38% in 2022 against a maximum downside of 101.1% in 2022.
  • A 4-year view of Short-Term Debt repayments shows it stood at $85043.0 in 2021, then soared by 1367.38% to $1.2 million in 2022, then fell by 17.15% to $1.0 million in 2023, then plummeted by 32.16% to $701411.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Short-Term Debt repayments are $701411.0 (Q4 2025), -$617961.0 (Q3 2025), and $1.0 million (Q2 2025).